Research programme: anticancer therapeutics - AEterna Zentaris

Drug Profile

Research programme: anticancer therapeutics - AEterna Zentaris

Alternative Names: D 87264; D-81050; D-82318; Microtubule inhibitors - AEterna Zentaris; Tubulin polymerisation inhibitors - AEterna Zentaris; ZEN 011; ZEN-014

Latest Information Update: 13 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zentaris
  • Developer AEterna Zentaris Inc
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cytoskeletal protein inhibitors; KIF11 protein inhibitors; Mitosis inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 13 May 2011 Discontinued - Preclinical for Solid tumours in Germany (PO)
  • 07 Nov 2007 Three compounds have been selected for further preclinical development
  • 06 Mar 2006 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top